Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2

被引:15
|
作者
Petrak, Russell M. [1 ]
Skorodin, Nathan C. [1 ]
Van Hise, Nicholas W. [1 ]
Fliegelman, Robert M. [1 ]
Pinsky, Jonathan [2 ]
Didwania, Vishal [3 ]
Anderson, Michael [4 ]
Diaz, Melina [5 ]
Shah, Kairav [5 ]
Chundi, Vishnu V. [6 ]
Hines, David W. [6 ]
Harting, Brian P. [7 ]
Sidwha, Kamo [6 ]
Yu, Brian [6 ]
Brune, Paul [8 ]
Owaisi, Anjum [9 ]
Beezhold, David [3 ]
Kent, Joseph [10 ]
Vais, Dana [6 ]
Han, Alice [6 ]
Gowda, Neethi [11 ]
Sahgal, Nishi [12 ]
Silverman, Jan [13 ]
Stake, Jonathan [14 ]
Nepomuceno, Jenie [15 ]
Heddurshetti, Renuka [16 ]
机构
[1] Metro Infect Dis Consultants, Burr Ridge, IL 60527 USA
[2] Metro Infect Dis Consultants, Naperville, IL USA
[3] Metro Infect Dis Consultants, Elmhurst, IL USA
[4] Metro Infect Dis Consultants, Kankakee, IL USA
[5] Metro Infect Dis Consultants, Atlanta, GA USA
[6] Metro Infect Dis Consultants, Chicago, IL USA
[7] Metro Infect Dis Consultants, Downers Grove, IL USA
[8] Metro Infect Dis Consultants, Kansas City, MO USA
[9] Metro Infect Dis Consultants, Bolingbrook, IL USA
[10] Metro Infect Dis Consultants, Oak Lawn, IL USA
[11] Metro Infect Dis Consultants, Troy, MI USA
[12] Metro Infect Dis Consultants, Hinsdale, IL USA
[13] Metro Infect Dis Consultants, Royal Oak, MI USA
[14] Metro Infect Dis Consultants, Waukegan, IL USA
[15] Metro Infect Dis Consultants, Mchenry, IL USA
[16] Metro Infect Dis Consultants, Detroit, MI USA
来源
关键词
D O I
10.1111/cts.12894
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Tocilizumab is an IL-6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). We evaluated patients treated with tocilizumab for a SARS-CoV-2 infection who were admitted between March 13, 2020, and April 16, 2020. This was a multicenter study with data collected by chart review both retrospectively and concurrently. Parameters evaluated included age, sex, race, use of mechanical ventilation (MV), usage of steroids and vasopressors, inflammatory markers, and comorbidities. Early dosing was defined as a tocilizumab dose administered prior to or within 1 day of intubation. Late dosing was defined as a dose administered > 1 day after intubation. In the absence of MV, the timing of the dose was related to the patient's date of admission only. We evaluated 145 patients. The average age was 58.1 years, 64% were men, 68.3% had comorbidities, and 60% received steroid therapy. Disposition of patients was 48.3% discharged and 29.3% died, of which 43.9% were African American. MV was required in 55.9%, of which 34.5% died. Avoidance of MV (P = 0.002) and increased survival (P < 0.001) was statistically associated with early dosing. Tocilizumab therapy was effective at decreasing mortality and should be instituted early in the management of critically ill patients with coronavirus disease 2019) COVID-19).
引用
收藏
页码:2146 / 2151
页数:6
相关论文
共 50 条
  • [1] Clinical value of procalcitonin in critically ill patients infected by SARS-CoV-2
    Garrido, Pedro
    Cueto, Pitter
    Rovira, Conxita
    Garcia, Elisabet
    Parra, Ana
    Enriquez, Raquel
    Pinos, Armando
    Sosa, Manuel
    Hernandez-Aguilera, Anna
    Vallverdu, Immaculada
    [J]. AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2021, 46 : 525 - 531
  • [2] Hypertriglyceridemia in Critically Ill Patients With SARS-CoV-2 Infection
    El Nekidy, Wasim S.
    Shatnawei, Abdullah
    Abdelsalam, Manal M.
    Hassan, Mariam
    Dajani, Ruba Z.
    Salem, Nouran
    St John, Terrence J. Lee
    Rahman, Nadeem
    Hamed, Fadi
    Mallat, Jihad
    [J]. ANNALS OF PHARMACOTHERAPY, 2022, 56 (06) : 637 - 644
  • [3] CytoSorb purification in critically ill SARS-CoV-2 patients
    Pieri, Marina
    Fominskiy, Evgeny
    Nardelli, Pasquale
    Bonizzoni, Matteo A.
    Scandroglio, Anna M.
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2022, 45 (02): : 216 - 220
  • [4] CytoSorb purification in critically ill SARS-CoV-2 patients
    Pieri, Marina
    Fominskiy, Evgeny
    Nardelli, Pasquale
    Bonizzoni, Matteo A
    Scandroglio, Anna M
    [J]. International Journal of Artificial Organs, 2022, 45 (02): : 216 - 220
  • [5] Observations of nemaline bodies in muscle biopsies of critically ill patients infected with SARS-CoV-2
    Vandenabeele, Frank
    Stevens, Sjoerd
    Snijders, Tim
    Stessel, Bjorn
    Dubois, Jasperina
    van Loon, Luc J. C.
    Lambrichts, Ivo
    Agten, Anouk
    [J]. MICROSCOPY, 2023, 72 (05) : 388 - 394
  • [6] QT Prolongation in Critically Ill Patients With SARS-CoV-2 Infection
    El Nekidy, Wasim S.
    Almuti, Khalid
    ElRefaei, Hazem
    Atallah, Bassam
    Mohammad, Lana M.
    AlMahmeed, Wael
    Badr, Mohamed
    Abdallah, Khaled
    Hamed, Fadi
    Mallat, Jihad
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022, 27
  • [7] HYPERTRIGLYCERIDEMIA IN CRITICALLY ILL SARS-COV-2 PATIENTS RECEIVING PROPOFOL
    Niss, Hannah
    Shemanski, Shelby
    Mohamed, Adham
    Holmes, Ashley
    Ploetz, Jeannette
    [J]. CRITICAL CARE MEDICINE, 2022, 50 (01) : 110 - 110
  • [8] Volume Balance and AKI in Critically Ill Patients with SARS-CoV-2
    Gunning, Samantha
    La, Ashley
    Hung, Anthony
    Rubin, Daniel S.
    Koyner, Jay L.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 67 - 67
  • [9] Clinical features of critically ill patients infected with SARS-CoV-2 outside Wuhan with and without diabetes
    Xiaojuan Peng
    Yanfang Chen
    Liangfei Deng
    Qi Liu
    Qing Li
    Jie Xiong
    Ying Shi
    Shaohui Tang
    [J]. International Journal of Diabetes in Developing Countries, 2020, 40 : 482 - 490
  • [10] Persistence of live virus in critically ill patients infected with SARS-COV-2: a prospective observational study
    Duane J. Funk
    Jared Bullard
    Sylvan Lother
    Gloria Vazquez Grande
    Lauren Garnett
    Kaylie Doan
    Kerry Dust
    Anand Kumar
    Guillaume Poliquin
    Jim Strong
    [J]. Critical Care, 26